Radioiodinated (I-125) Monoclonal Antibody 425 in the Treatment of High Grade Glioma Patients

Emrich, Jacqueline; Brady, Luther W.; Quang, Tony S.; Class, Reiner; Miyamoto, Curtis; Black, Perry; Rodeck, Ulrich

doi:10.1097/01.coc.0000041009.06780.e5

Cited by 38 publications

(34 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…91 The iodine-125 radiolabeled anti-EGFR antibody mAb 425 given as adjuvant treatment after surgery and radiotherapy for high-grade gliomas was well tolerated. 21,92 Median survival was 13 months to 16 months in GBM and 51 months in anaplastic astrocytoma. 21,92 However, a randomized trial of adjuvant radioimmunotherapy with iodine-125 labeled mAb 425 showed no additional benefit compared to surgery and radiotherapy alone.…”

Section: Clinical Trials Of Egfr Therapeutic Agentsmentioning

confidence: 99%

“…21,92 Median survival was 13 months to 16 months in GBM and 51 months in anaplastic astrocytoma. 21,92 However, a randomized trial of adjuvant radioimmunotherapy with iodine-125 labeled mAb 425 showed no additional benefit compared to surgery and radiotherapy alone. 93 Only a few trials have reported on EGFRvIII specific therapy in glioma patients (Table 1).…”

Section: Clinical Trials Of Egfr Therapeutic Agentsmentioning

confidence: 99%

“…56 Many agents that target wt EGFR also target the EGFRvIII, and a few EGFRvIII-specific agents have also been developed. [20][21][22][23]57,58 Approaches to EGFR inhibition relevant to GBM include monoclonal antibodies (naked and conjugated), tyrosine kinase inhibitors and immunotherapeutic strategies such as vaccines.…”

Section: Pre-clinical Data About Targeted Therapeutics Against the Egmentioning

confidence: 99%

See 2 more Smart Citations

The EGFRvIII variant in glioblastoma multiforme

Gan

Kaye

Luwor

2009

Journal of Clinical Neuroscience

335

253

View full text Add to dashboard Cite

Section: Clinical Trials Of Egfr Therapeutic Agentsmentioning

confidence: 99%

Section: Clinical Trials Of Egfr Therapeutic Agentsmentioning

confidence: 99%

Section: Pre-clinical Data About Targeted Therapeutics Against the Egmentioning

confidence: 99%

See 1 more Smart Citation

The EGFRvIII variant in glioblastoma multiforme

Gan

Kaye

Luwor

2009

Journal of Clinical Neuroscience

335

253

View full text Add to dashboard Cite

“…Safe administration of the labeled antibody was demonstrated. Ten-year follow-up showed a median OS of 13.4 months in patients with GB [54].…”

Section: Trials With Co-therapy Of Egfr Inhibitors and Mtor Inhibitorsmentioning

confidence: 97%

Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives

2010

View full text Add to dashboard Cite

Despite advances in the understanding of the molecular biology of glioblastomas (GB), these neoplasms still are incurable with conventional therapies. Current efforts therefore focus on the development of new molecular approaches that exploit the genetic aberrations of cancer cells. Based on their frequent activation or mutation in human GB and their paramount role for the maintenance of the neoplastic phenotype, both the epidermal growth factor receptor (EGFR) and the mammalian target of rapamycin (mTOR) are plausible targets for molecular therapies. However, clinical trials with drugs targeting EGFR or mTOR, so far, have produced largely disappointing results. In this article, we review strategies targeting EGFR and mTOR as therapies for malignant glioma. Recent advances in the understanding of the complex signaling network involved are highlighted and the results of clinical trials are summarized. Mechanisms of resistance are explored, and potential future directions as well as trends in preclinical and clinical development are discussed.

show abstract

“…The initial findings were presented in the Proceedings of the Seventh International Meeting on Progress in Radio-Oncology in May 2002 (31), and the report of the final results was recently published (32). In that study, from January 29, 1987 to January 25, 1997, 180 patients diagnosed with GBM and AAF were treated as outpatients with an average of three weekly intravenous or intra-arterial injections of approximately 50 mCi of 125 IMAb to avoid bone marrow transplantation.…”

mentioning

confidence: 98%